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Abstract 
New strategies for immune modulation have shown real promise in regenerative medicine as 
well as the fight against autoimmune diseases, allergies and cancer. Dendritic cells (DCs) are 
gatekeepers of the immune system and their ability in shaping the adaptive immune responses 
makes DCs ideal targets for immune modulation. Carbohydrates are abundant in different 
biological systems and are known to modulate DC phenotype and function. However, how 
simple monosaccharides instruct DC function is less well understood. In this study we used a 
combinatorial array of immobilized monosaccharides to investigate how they modulate DC 
phenotype and function, and crucially the impact of such changes on downstream adaptive 
immune responses. Our data show a selection of monosaccharides significantly suppress 
lipopolysaccharide (LPS) induced DC activation as evidenced by reduction in CD40 
expression, IL-12 production and 2,3 indoleamine dioxygenase activity, while inducing a 
significant increase in IL-10 production. These changes are indicative of induction of an anti-
inflammatory or regulatory phenotype in DCs which was further confirmed in DC-T cell co-
cultures where DCs cultured on the ‘regulatory’ monosaccharaide coated surfaces were 
shown to induce naïve T cell polarization towards regulatory phenotype. Our data also 
highlighted a selection of monosaccharides that are able to promote mixed Treg and Th17 
cell differentiation, a T cell phenotype expected to be highly immune suppressive. These data 
show the potential immunomodulatory effects of immobilized monosaccharides in priming 
DCs and skewing T cell differentiation towards an immune-regulatory phenotype. The ability 
to fine tune immune responses using these simple carbohydrate combinations (e.g. as 
coatings for existing materials) can be utilized as novel tools for immune modulation with 
potential applications in regenerative medicine, implantable medical devices and wound 
healing where reduction of inflammatory responses and maintaining immune homeostasis are 
desirable.  
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90%2-amino-2-deoxy-b-D-galactose+10%1-amino-1-deoxy-b-D-mannose, (Gal2-Man1); 2-
amino-2-deoxy-b-D-galactose+10%2-amino-2-deoxy-b-D-mannose, (Gal2-Man2); 40%1-
amino-1-deoxy-b-D-mannose + 60%2-amino-2-deoxy-b-D-mannose, (Man1-Man2); 50%1-
amino-1-deoxy-b-D-galactose +50%2-amino-2-deoxy-b-D-galactose (Gal1-Gal2);  
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1. Introduction  
The immune system plays a central role in response to foreign materials we are exposed to, 
from pathogens to biomaterials used for therapeutic purposes [1]. The ability to suppress 
adverse immune responses and promote beneficiary anti-inflammatory and pro-healing 
immune responses will improve the clinical outcome for implanted materials whether used as 
scaffolds for regenerative medicine applications or in medical devices[2]. Dendritic cells 
(DCs) are the immune system’s sentinels that sense their surrounding environment using a 
host of different pattern recognition receptors (PRRs) [3]. Upon activation, DCs migrate to 
draining lymph nodes where they prime naïve T cells and instruct their differentiation 
towards different functional phenotypes (e.g. Th1, Th2, T-reg or Th17), a process that is 
heavily influenced by DCs’ surface phenotype, cytokine profile and expression of other 
immune-regulatory molecules [4-6]. DCs constantly sample their environment using PRRs, 
which enable them to transfer information about the nature of antigens and foreign materials 
they have encountered in peripheral tissues to T cells in lymph nodes [7]. Carbohydrates are 
an integral part of almost all proteins and play key roles in biological processes including self 
and non-self recognition pathways and their associated signalling pathways. The wide range 
of functions carried out by carbohydrates is reflected in their structural diversity [8, 9]. The 
C-type lectin receptors (CLRs) are amongst many PRRs expressed by DCs and belong to a 
family of carbohydrate-binding proteins, that recognise a broad repertoire of self and non-self 
ligands, with diverse functions in innate and adaptive immunity and maintaining homeostasis 
[10]. Different CLRs recognise different carbohydrates moieties and interaction between a 
given CLR and its ligand could influence DC phenotype and cytokine profile as well as 
downstream events leading to T cell polarization [11, 12]. Prime examples of these are the 
carbohydrate moieties decorating allergens and pathogen glycoproteins which modulate the 
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immune response depending on the CLR counterparts [12-15] leading to inflammatory 
responses or immune evasion [16-18].  In parallel to their role in initiating immune responses, 
DCs also play a key role in maintaining tissue homeostasis and immune regulation. Immune 
regulatory enzymes such as 2,3 indoleamine dioxygenase  have been implicated in these 
processes [19, 20]. IDO is a rate-limiting enzyme that converts L-tryptophan into kynurenine, 
a metabolite with well-established immune modulatory properties [13, 21, 22]. This is 
exemplified in tumours with high IDO activity leading to depletion of tryptophan and an 
increase in kynurenine levels that suppresses the immune activity that contributes to survival 
of the tumour [23].  
Different surface modification strategies have been used to develop materials with higher 
immune compatibility or the ability to modulate immune responses [24], however, despite 
their  strong immune modulatory properties carbohydrates have not been extensively 
considered in this context. While extensive literature on the immune modulatory properties of 
polysaccharides exist, the immune modulatory potential of monosaccharides is not well 
studied. This is despite many advantages in using monosaccharides in immune modulation 
including the ability to synthesise, modify and characterise highly pure preparations. In this 
study we use a combinatorial library of polymer tethered surface immobilized 
monosaccharides (manno-, galacto- and fuco-) and investigate their impact on DC phenotype, 
cytokine profile and IDO activity, as well as the ability of carbohydrate primed DCs to 
instruct T cell differentiation towards distinct functional phenotypes.  
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2. Materials and methods 
2.1.Generation of human DCs from peripheral blood monocytes 
This was done as we have previously described [25]. Briefly, buffy coats were obtained from 
healthy donors following ethics committee approval and informed written consent (National 
Blood Service, UK). Peripheral blood monocytes (PBMCs) separation was done by means of 
density gradient centrifugation on Histopaque (Sigma-Aldrich, UK). CD14+ monocytes were 
isolated using magnetic assisted cell sorting (Miltenyi Biotech, UK). Purity of isolated 
monocytes was confirmed by flow cytometry and was consistently >95% (Supplementary Fig 
1). Purified CD14 monocytes were supplemented with RPMI media containing 10% heat 
inactivated Foetal Bovine Serum (FBS), 100mg/mL streptomycin, 100U/mL penicillin and 
2mM L-glutamine (all from Sigma-Aldrich). To generate immature DCs, monocytes were 
then seeded (1x106 cell per well) in a 24 well tissue culture plate with the presence of 50 
ng/mL GM-CSF and 250 U/mL IL-4 (both from Miltenyi biotech) and incubated at 37ºC in a 
5% CO2 humidified incubator for 6 days for differentiation where fresh media was added on 
day 3. Immature DC phenotype and maturation were confirmed through flowcytometry 
(Supplementary Fig 2). 
2.2. Polymerization of N-hydroxyethylacrylamide  
N-Hydroxyethyl acrylamide (1 g, 8.69 mmol), pentafluorophenyl 2- 
(dodecylthiocarbonothioylthio)-2-methylpropionic acid (PFP-DMP) (0.1844 g, 0.35 mmol), 
4,4′-Azobis(4-cyanovaleric acid) (ACVA) (0.0195 g, 0.069 mmol) were dissolved in 50:50 
toluene:methanol (4 mL). Mesitylene (150 µL) was added as an internal reference. An aliquot 
was taken for NMR analysis in CDCl3. The solution was degassed under N2 for 30 mins. The 
reaction was stirred at 70 °C for 90 mins. An aliquot was taken for NMR analysis in MeOD 
to determine conversion. The reaction was rapidly cooled in liquid nitrogen and precipitated 
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into diethyl ether. The polymer was reprecipitated into diethyl ether from methanol twice to 
yield a yellow polymer product that was dried under vacuum. 97 % conversion by NMR, Mn 
(Theoretical) = 3400 g.mol-1 Mn (SEC) = 4100 g.mol-1 Mw/Mn (SEC) = 1.14. 
2.3. Synthesis of 1-amino-1-deoxy-mannose, -galactose and -fucose 
Galactose, mannose or fucose (1 g) were stirred in 10 mL aqueous saturated ammonium 
carbonate for 2-5 days, ensuring the solution remained saturated. Reaction completion was 
determined by mass spectrometry. After reaction completion, the solution was freeze dried. 
Excess ammonium carbonate was removed by addition of warm methanol. After complete 
evolution of CO2, the methanol was removed in vacuuo. ESI-MS:  1-amino-1-deoxy-mannose 
(C6H13NO5) M = 179.17 expected, [2M-H]- observed 359.1 (C12H25N2O10), 1-amino-1-deoxy-
galactose (C6H13NO5) M = 179.17 expected, [2M-H]- observed 359.1 (C12H25N2O10) and 1-
amino-1-deoxy-fucose (C6H13NO4) M = 163.17 expected, [M-H]- observed 162.1.   
2.4. End group modification of PFP-polyN-hydroxyethylacrylamide using amino 
monosaccharides 
In a typical reaction, PFP-pHEA (100 mg, 0.029 mmol), 2-amino-2-deoxy-galactose (26 mg, 
5 eq.) was dissolved in 2 mL DMF with a drop of TEA. The reaction was stirred at room 
temperature for 16 h. The polymer was precipitated into diethyl ether from methanol three 
times. The polymer was dialyzed against water using 1K MWCO tubing to remove excess 
unreacted amino-sugar and freeze dried to result in. IR indicated loss of C=O stretch 
corresponding to the PFP ester and 19F NMR confirmed the loss of the PFP group. This was 
carried out with 1-amino-1-deoxy-β-D-galactose, (Gal1) 2-amino-2-deoxy-β-D-galactose 
(Gal2), 1-amino-1-deoxy-β-D-mannose (Man1), 2-amino-2-deoxy-b-D-mannose (Man2), 1-
amino-1-deoxy-β-D-fucose, as well as ethanolamine as a non-monosaccharide terminated 
control [26, 27]. The isomer1 or isomer2 designation is based on whether the carbohydrate is 
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amino-functionalized at C1 or C2 of glycan ring and attached to the N-hydroxyethyl 
acrylamide polymer by an amide bond (Fig1). 
2.5. Functionalization of 96-well polystyrene plates with monosaccharide -
functionalized polymers and fabrication of combinatorial monosaccharide 
libraries   
To make combinatorial libraries of different monosaccharides a ‘grafting to’ approach was 
used as we have previously described [28-32] with minor adjustments. The method involves 
synthesizing a polymer to enable anchoring the monosaccharides of interest to the epoxide-
functionalized polystyrene plate. Briefly, the polymer is engineered to have a carbohydrate 
capture terminus and an immobilization terminus. N-hydroxyethyl acrylamide was 
polymerized to a degree of polymerization (DP) of 20 using reversible addition-
fragmentation chain transfer (RAFT) polymerization mediated by a pentafluorophenol (PFP) 
α-terminated RAFT agent (Fig 1A). Monosaccharides (mannose, galactose, fucose) were 
captured onto this polymer scaffold using amino-monosaccharides by simple substitution of 
the terminal PFP unit. The monosaccharide-functionalized polymers were then immobilized 
onto 3D-epoxy 96-well polystyrene plates using the ω-terminal thiol from the RAFT agent 
(Fig 1B) via a simple incubation and washing steps. To achieve this, a 0.1 mg.mL-1 solution 
of monosaccharide-functionalized PHEA was made up in milliQ water. Solutions of 
polymers were made up and 100 µL of each of these solutions was applied to a branched and 
spacered (50 nm thickness) epoxy functionalized flat bottom 96-well polystyrene plates and 
allowed to react for 30 mins at room temperature. Each solution was made in triplicate. After 
30 mins incubation, the solution was removed, and the well was washed with water three 
times to remove any unreacted polymer. Various combinations of monosaccharides were 
prepared, ranging from 100% of one monosaccharide (mannose, galactose or fucose) to 100% 
of another (mannose, galactose or fucose), in steps of 10% to make a total of 11 different 
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wells in triplicate for each library (Supplementary Table 1). This post-polymerization route 
ensures that all the polymers have the same initial chain length distribution and therefore 
reduced the variability between the libraries produced but allows for versatile end-group 
functionalization to make simple libraries with differing carbohydrate densities.  
 
Figure 1: Synthetic route to carbohydrate coated plates. (A) Polymerization of N-
hydroxyethyl acrylamide via RAFT polymerization to a degree of 20 and subsequent 
carbohydrate functionalization of PHEA. (B) Immobilization of carbohydrate terminated 
polymers onto epoxy-coated 96 well plates [33]. (C) Monosaccharides used in the study from 
left to right, 1-amino-1-deoxy galactose, 2-amino-2-deoxy galactose, 1-amino-1-deoxy 
mannose, 2-amino-2-deoxy mannose and 1-amino-1-deoxy fucose.   
 
 
2.6. Cell culture and screening of DC response 
Each of the monosaccharide functionalized wells was sterilized with 70% ethanol and excess 
ethanol was washed with sterile PBS. Immature dendritic cells were incubated in each well 
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for 24 hrs where each well was seeded with 1x105 DCs. Some wells were stimulated with of 
LPS from E. coli (10 ng/mL). Control conditions included well with OH-terminated PHEA 
(i.e. no carbohydrate coating), LPS only stimulation and un-stimulated DCs.  
2.7. Quantification of Indoleamine 2,3-dioxygenase activity 
After stimulation, IDO activity was measured by quantification of the levels of kynurenine in 
the culture supernatant using a colorimetric assay as we have described previously described 
[25, 34, 35]. The absorbance was determined using Promega GlowMax Explorer plate reader 
on a wavelength of 490 nm. The results are plotted against L-kynurenine standards with 
concentrations ranging from 0-200 mM. 
2.8. Flow cytometry 
Cells were harvested from the 96 well plates to FACS tubes and washed with PBA (PBS with 
0.5% bovine serum albumin and 0.1% sodium azide) as described previously [13].  DCs were 
then incubated with labelled antibodies CD274 (APC clone REA1197), CD40 PE (clone 
HB14), CD86 FITC (clone FM95) and isotype matched mouse antibody controls (all from 
Miltenyi biotech) for 20 minutes in the dark at 4 °C. Cells were then washed in PBA twice 
and fixed with 4% paraformaldehyde until analysis. All samples are analysed using FC500 
Flow cytometer (Beckman Coulter) and data analysis was carried out using Weasel software. 
2.9. Cytokine quantification  
Cell-free culture supernatants were collected and stored at -80 °C before analysis. The levels 
of cytokines IL-10, IL-12p70, IL-17, IL-4 and IFNγ were measured by sandwich ELISA 
using the Duo Set ELISA kit (R&D Systems, UK) according to manufacturer’s instructions. 
2.10. Dendritic cells-T cells co-cultures 
Autologous co-cultures were carried out with monosaccharides primed DC as previously 
described [25, 35]. Briefly, T cells were isolated from PBMCs using a pan T cell isolation kit 
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followed by depletion of CD45RO+ memory T cells using CD45RO immunomagnetic beads 
(both from Miltenyi Biotec). Naïve (CD45RO-) T cells were co-cultured with DCs at a 1:10 
DC to T cell ratio in RPMI1640 supplemented with 5% human AB serum 100 mg/mL 
streptomycin, 100 U/mL penicillin and  2 mM L-glutamine (all from Sigma-Aldrich).  On 
day 3 cells were supplemented with IL-2 (2 ng/ml). After 6 days of co-culture, cells were 
stimulated with anti-CD3 and anti-CD28 overnight followed by quantifying T cells cytokine 
profile.   
2.11. RNA Isolation & RT-qPCR 
mRNA extraction and isolation were carried out using the RNeasy kit (QIAGEN) and cDNA 
synthesis was carried out using qPCR synthesis kit (PCRBIOSYSTEMS) according to 
manufacturer’s instructions. Real time PCR was carried out using SYBR Green qPCR Master 
Mix (PCRBIOSYSTEMS) and the qPCR cycler Stratagene MxPro 3005P qPCR System 
(Stratagene, La Jolla, CA). Primers used are GAPDH (forward) 5`-
GAGTCAACGGATTTGGTCGT-3`, GAPDH (reverse) 5`-
GACAAGCTTCCCGTTCTCAG-3`; FOXP3 (forward) 5`- GTGGCCCGGATGTGAGAAG-
3`, FOXP3 (reverse) 5`- GGAGCCCTTGTCGGATGATG-3`; RORγt (forward) 5`- 
CCTGGGCTCCTCGCCTGACC-3`, RORγt (reverse) 5`- 
TCTCTCTGCCCTCAGCCTTGCC -3`. The heat cycle was initiated at 95 for 2 min, 
followed by 40 cycles of 95 for 5 sec, then 65 for 25 sec and followed by 95 for 1 min, 55 30 
sec 95 30 sec. Sample values are relative to LPS only and are normalized to the house 
keeping gene GAPDH. All samples are run in triplicates. 
2.12. Statistical analysis 
Statistical significance of the Data was obtained using GraphPad Prism 7 (GraphPad 
Software, San Diego, CA). Therefore, paired t tests or ordinary one-way ANOVA was used 
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when comparing between two groups. Statistically significant p values were considered to be 
equal or lower than 0.05. 
 
3. Results  
3.1. Screening a combinatorial library of immobilized mannose, galactose and fucose 
for their ability to modulate DC phenotype 
To investigate the effect of surface immobilized monosaccharides on DC phenotype and IDO 
activity, immature and LPS stimulated DCs were cultured on the monosaccharide 
immobilized polystyrene plates containing different ratios of amino-fucose, amino-mannose 
and amino-galactose (where the number after each glycan indicates the ring-position of the 
amine, Fig 1) for 24hrs followed by flow cytometric analysis of their surface phenotype and 
quantifying kynurenine in the supernatant as a surrogate for IDO activity. For analysing DC 
phenotype, we chose a selection of surface receptors linked to immune stimulation (CD40 
and CD86) or inhibition (CD274 or Programmed Death Ligand 1 (PDL-1)).  Unsurprisingly, 
none of the monosaccharide combinations seemed to influence immature DC phenotype 
(Supplementary Fig 3) since monosaccharides are abundant in the human body contributing 
to cell membrane physiology and metabolism hence without accompanying a potent stimulus 
(e.g. a danger signal)  the immune cells would not react to them [36]. However, flow 
cytometry data s(Fig 2 and Supplementary Figs 4-7) showed that 35 immobilized 
monosaccharides were able to significantly downregulate CD40 expression in LPS stimulated 
DCs. Interestingly all fucose containing carbohydrates induced significant suppression of 
CD40 expression. This was in contrast to all Gal1 with Man1 or Man 2 combinations o 
(except 60%Man240%Gal1 and 100%Gal1) which did not induce any significant changes in 
CD40 expression.  As indicated previously, the isomer1 or isomer2 designation is based on 
whether the carbohydrate is functionalized at C1 or C2 of the N-hydroxyethyl acrylamide 
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polymer respectively which seems to have an impact on how they interact with DCs. 
Furthermore, we observed an increase in CD274, the programmed death ligand 1 (PD-L1), 
expression in LPS stimulated DCs treated with all combinations of Gal2 with Man1 or Man2 
indicating a shift towards regulatory/inhibitory DCs. CD86 expression was higher in a 
number of conditions (particularly combinations of Gal1 and Gal2) however, these did not 
reach statistical significance (Fig 2 and Supplementary Figs 4-6). Nevertheless, at this stage 
of screening all monosaccharides, regardless to their impact of DCs’ surface phenotype, were 
taken forward for additional experimentation.  
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Figure 2: Flow cytometry data shown as a heat map summarising expression profile of three surface markers (CD86, CD40 and CD274) on DCs 
after incubation on immobilized monosaccharide libraries in the presence of a TLR4 ligand (LPS).  Unstimulated (immature) DCs were used as a 
negative control. All changes are expressed as a percentage of expression levels in mature (LPS stimulated) DCs. A reduction in CD40 
expression was observed in most conditions with highest reduction in fucose contained libraries compared to LPS alone. CD86 expression was 
higher in a number of conditions (particularly mixers of galactose1 and Gal2) however these did not reach statistical significance. CD274 (PD-
L1) expression showed a significant increase in Man1 and Gal2 combinations. Data is shown as mean ± SD of three independent donors where 
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.  
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3.2. The effect of immobilized monosaccharides on DC IDO activity  
Next, to understand the impact of monosaccharides on DC immunogenicity we investigated 
IDO activity in LPS stimulated DCs cultured on a selection of monosaccharides predicted to 
have pro- or anti-inflammatory properties based on their impact on DC phenotype. Data from 
these experiments show significant reductions in the IDO activity particularly in 
combinations mainly constituted of both isoforms of the carbohydrate where the carbohydrate 
is functionalized at C1 or C2 of the N-hydroxyethyl acrylamide polymer for isomer1 or 
isomer2 respectively (Fig 3). These findings corroborate observed changes in DCs phenotype 
(e.g. suppression of CD40 expression)  and suggest DCs primed on a number of immobilized 
monosaccharides acquire distinct pro- or anti-inflammatory phenotypes  [37, 38]. 
Interestingly, similar mixtures of monosaccharides in soluble form did not induce any 
significant changes in IDO activity (Supplementary Fig 8). 
 
Figure 3: Data obtained from indoleamine 2,3-dioxygenase activity in dendritic cells treated 
with the immobilized monosaccharides in the presence of a TLR4 ligand (LPS). Reduction in 
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indoleamine 2,3-dioxygenase activity is prominent in monosaccharide combinations 
consisting of the 2 isomers of the same monosaccharide while others have a reduction in 
indoleamine 2,3-dioxygenase but not as significant as the latter compared to dendritic cells 
treated with LPS alone. Data is shown as mean ± SD of three independent donors where *p < 
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. 
 
 
3.3. Immobilized Gal1, Man1-Man2, Man1-Gal2 and Man2-Gal2 significantly 
increase the production of IL-10 and suppress IL-12 production while Gal1-Gal2 
suppresses both cytokines in TLR4 stimulated DCs. 
To better understand the effect of different monosaccharides shown to modulate DC 
phenotype and IDO activity on DC function, we also investigated their impact on DC 
cytokine profile focusing on IL-12 and IL-10 as prototypic pro- and anti-inflammatory 
cytokines respectively. DCs stimulated with LPS and cultured on 100%Galactose1 (Gal1), 
40%Mannose1+60%Mannose2 (Man1-Man2), 10%Mannose1+90%Galactose2 (Man1-Gal2) 
and 10%Mannose2+90%Galactose2 (Man2-Gal2) coated wells showed significant increase in 
IL-10 while suppressing IL-12 production compared to LPS only (Fig 4 and supplementary 
Fig 9). These findings are in line with the observed changes in DC phenotype showing 
suppression in CD40 expression in response to the same monosaccharide combinations. An 
intriguing finding was identifying sugar combinations (e.g. 50%Gal1+50%Gal2 (Gal1-Gal2)) 
that were able to lower DC IDO activity as well as supressing both IL-10 and IL-12 levels. 
These carbohydrate combinations are expected to significantly supress DC immunogenicity.    
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Figure 4: Cytokine profile of dendritic cells treated with immobilized monosaccharides in the presence of a TLR4 ligand (LPS). Gal1, Man1-
Man2, Man1-Gal2 and Man2-Gal2 combinations induce a significant in IL-10 production and suppression in IL-12 while Gal1-Gal2 supresses 
both cytokines in response to LPS stimulation compared to LPS alone. Data are presented as the % change compared to levels of cytokines 
produced in response to LPS stimulation for each donor. Data is shown as mean ± SD of ≥3 independent donors where *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001
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3.4. Suppressing IDO activity using a competitive inhibitor leads to a similar 
cytokine profile to monosaccharide primed DCs 
To investigate whether the observed changes in DCs cytokine profile could be due to changes 
in IDO activity we treated LPS stimulated DCs with 1-methyl-DL-tryptophan (MT), a 
competitive inhibitor of IDO, followed by quantifying IL-12  and IL-10 production [22].  The 
data show that MT suppressed IDO activity in DCs in a dose dependent manner (Fig 5A). 
The level of reduction in IDO activity in the chosen MT concentration range was comparable 
with the levels observed in DCs primed with Gal1, Man1-Man2, Man1-Gal2, Man2-Gal2, 
Gal1-Gal2. Furthermore, the MT treated DCs showed a reduction in IL-12 production, 
similar to their monosaccharide treated counterparts. This data suggests a correlation between 
changes in IDO activity and IL-12 production. 
Interestingly, in the case of IL-10 in lower concentrations of MT, where IDO activity is only 
reduced by around 50%, there is an increase in IL-10 production, albeit not statistically 
significant, which is only suppressed with increasing concentrations of MT and marked 
reduction in IDO activity to around 10% of LPS only condition. This is consistent with data 
from monosaccharaide treated DCs showing while a 50% reduction in IDO activity correlates 
with a significant suppression of IL-12 production, IL-10 production is increased. 
Collectively this data suggests that DCs pro- or anti-inflammatory phenotypes correlates with 
the level of IDO activity where a change in IDO is directly proportional to IL-12 production 
whereas IL-10 levels seem to show a biphasic correlation to IDO activity (Fig 5B, 5C).  
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Figure 5: DCs were treated with LPS and varying concentrations of 1-methyle-DL-tryptophan (a competitive indoleamine 2,3-dioxygenase 
inhibitor) to assess the correlation of IDO activity to IL-10 and IL-12 production. A) MT suppresses IDO activity in a dose dependent manner. 
B) IL-12 production shows a proportional relationship IDO activity while C) IL-10 production shows a peak in lower concentrations of the 
inhibitor (0.004 mM and 0.01 mM) where IDO is at 50% reduction while after almost compelet inhibition of IDO activity (at 0.4 mM) there is 
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still IL-10, but not IL-12 production.  Data presented as mean ± SD of ≥3 independent donors where *p < 0.05, **p < 0.01, ***p < 0.001, ****p 
< 0.0001
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3.5. DCs conditioned by Gal1 and Gal1-Gal2 bias T cell differentiation towards IL-
10 and IL-17 producing cells respectively   
Gal1, Man1-Man2, Man1-Gal2, Man2-Gal2 and Gal1-Gal2 modulated DC surface 
stimulatory ligands, cytokine production and IDO activity in LPS stimulated DCs suggesting 
a regulatory phenotype. These conditions were selected for investigating downstream effects 
on T cell differentiation in DC-T cell co-culture studies. Co-cultures were carried out using 
autologous naïve T cells and DCs, where DCs were primed with the selected immobilized 
carbohydrates in the presence of LPS for 24hrs and then co-cultured with naïve T cells for 6 
days. Data show a significant increase in IL-10 production by naïve T cells in Gal1, Gal1-
Gal2 and Man2-Gal2 conditions (Fig 6). An interesting finding was that T cells co-cultured 
with Gal1 and Gal1-Gal2 treated DCs showed a significant increase in IL-17 production 
compared to LPS alone whereas a decrease in IL-17 can be noted in Man1-Gal2. These data 
also show a significant decrease in IL-4 production by T cells co-cultured with Gal1-Gal2 
and Man2-Gal2 treated DCs while IFN-γ levels remain unchanged compared to LPS alone for 
all conditions.  
From these data, we hypothesized that naïve T cells co-cultured with Gal1 and Gal1-Gal2 
treated DCs have acquired mixed  anti-inflammatory and pro-inflammatory phenotypes 
similar to what has been recently described in the context of some inflammatory conditions 
and cancers [39]. To further confirm the phenotype of these cells we investigated expressing 
of FOXp3 and RORγt, major Treg and Th17 transcription factors respectively, using real 
time polymerase chain reaction (RT-PCR). We were able to confirm the expression of both 
FOXp3 and RORγt indicating the generation of cells with a mixed T-reg/Th17 phenotype on 
immobilized Gal1 and Gal1-Gal2 (Fig7). Interestingly, Man1-Gal2 showed a decrease in IL-
17 production and RORγt gene expression indicating that the inclusion of mannose changed 
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cell differentiation away from Th17 and towards Th1 as evidenced by significant decrease in 
IL-17 and unchanged levels of IFN-γ.  
 
Figure 6: Co-cultures of T cells with monosaccharide primed DCs were set up to investigate 
effect of monosaccharides on T cell differentiation using their cytokine profile.  IL-10, IFNγ, 
IL-4 and IL-17 were selected as prototypic Treg, Th1, Th2 and Th17 cytokines. An increase 
in IL-10 production can be noted in all conditions reaching statistical significance in Gal1, 
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Gal1-Gal2 and Man2-Gal2. Interestingly the same conditions also show increase in IL-17 
productions with highest increase observed in Gal1 and Gal1-Gal2. A significant decrease in 
IL-17 can be noted for Man1-Gal2 showing a shift of the immune system away from Th17 
and into Th1. Data is shown as mean ± SD of ≥4 independent donors where *p < 0.05, **p < 
0.01, ***p < 0.001, ****p < 0.0001. 
 
Figure 7: RT-PCR experiments to quantify FOXP3 and RORγt expression to further confirm 
T cell phenotype. Significant increase in FOXP3 expression can be seen in Gal1 and Gal1-
Gal2. Interestingly a significant increase in RORγt production can be noted in Gal1-Gal2, 
Gal1 whereas reduction in Man1-Gal2 indicating a possible presence of Th17 and T-regs in 
the population for Gal1-Gal2, Gal1 and the absence of Th17 in Man1-Gal2 condition. Data is 
shown as mean± SD of triplicates of 3 independent donors. 
 
 
4. Discussion  
There is increasing interest in biomaterials that are able to modulate immune responses to 
promote healing and suppress adverse immune responses with significant focus on 
modulating macrophage phenotype [40]. There are encouraging data from use of polymers, 
small molecules and materials with defined shape and topographies that are able to dampen 
adverse immune responses [41-44]. However, despite its importance in determining the fate 
of implanted materials [45], controlling adaptive immune responses through material 
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engineering  has remained relatively unexplored. The potent immune modulatory properties 
of carbohydrates and many tools available for their modification and incorporation into 
existing materials make them attractive candidates for engineering new materials with 
immune-instructive properties. 
The central role of DCs in shaping adaptive immune responses means these cells are ideal 
targets for immune modulation including controlling immune responses against implanted 
materials [46]. Carbohydrates decorating pathogens and tumour cells have been known to 
trigger protective or inhibitory immune responses by modulating DC function, which 
typically underpin immune evasion or survival of tumours [47, 48]. The latter is mainly 
through skewing DCs response from inflammatory to tolerogenic, which in turn, suppresses 
the immune responses against tumour cells [49]. This is in line with our data showing a 
number of ‘hit’ conditions (e.g. Gal1, Gal1-Gal2, Man1-Gal2, Man2-Gal2 and Man1-Man2) 
were able to induce a regulatory phenotype in DCs as evidenced by a significant  reduction in 
expression of co-stimulatory molecule CD40 and increase in tolerogenic CD274 (PDL-1) 
expressions in LPS challenged DCs. CD40 has been shown to play an important role in 
supporting pro-inflammatory responses and Th1 differentiation through engaging CD154 (or 
CD40L) on T cells which is known to induce high levels of IL-12 production, a key pro-
inflammatory cytokine [38, 50], whereas CD274 (PDL-1) is an inhibitory ligand for T cell 
activation with a role in Treg development [51]. This is also consistent with how some 
pathogens modulate the immune system in their favour. For example, Hamilton et al. showed 
that Faciola hepatica tegumental glyco-antigens suppresses DC maturation by decreasing 
CD40 expression in DCs, contributing to the pathogen survival [52]. Interestingly, our data 
also showed that the same group of monosaccharides that suppressed CD40 expression and 
induced CD274 (PDL-1) expression could significantly suppress LPS induced IDO activity in 
DCs. IDO, is the rate limiting enzyme for the essential amino acid tryptophan catabolism and 
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is known for its modulatory effects on immune cells and importantly on DCs through 
different mechanisms such as depletion of tryptophan, producing immune regulatory 
metabolites like kynurenine [13, 35]. Despite some contradictory evidence on the correlation 
between IDO activity and DCs function, it is clear that suppression of IDO activity and 
reduced tryptophan levels in the microenvironment suppress inflammatory immune responses 
and could promote immune regulation [53-56]. This is also in line with studies showing 
increased levels of IDO activity in tumour environments which leads to depletion of 
tryptophan causing DCs switching to anergic state and ultimately survival of the tumour cells 
[57, 58]. To understand the importance of monosaccharides immobilisation in the observed 
effects on DCs,  we also treated DCs with a selection of monosaccharide combinations in 
soluble form. These experiments showed none of the soluble monosaccharide combinations 
had a significant impact on IDO activity (Supplementary Figs 8). These observations suggest 
that both receptor clustering or conformation of monosaccharides play an important role in 
their immune modulatory effects on DCs.   Nevertheless,  in are a large group of pathologies, 
including autoimmune and inflammatory diseases as well as adverse proinflammatory 
responses to implanted materials, ‘regulatory’ monosaccharides able to suppress IDO activity 
and promote tolerogenic DCs to suppress excessive will be highly desirable, and could play a 
significant role in developing new therapeutic strategies for these groups of pathologies [46, 
59, 60].  
Changes in DCs phenotype and IDO activity in ‘hit’ monosaccharide primed DCs also 
reflected in their pro- and anti-inflammatory cytokine profile. Specifically, LPS stimulated 
DCs cultured on Gal1, Gal1-Gal2, Man1-Gal2, Man2-Gal2 and Man1-Man2 showed a 
significant suppression in IL-12 production and an increase in IL-10. This is in line with how 
glycoantigens in some pathogens modulate DC function. For example, ManLam is a 
component of Mycobacterium tuberculosis cell membrane is terminated in mannose and its 
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interaction with DC-SIGN has been shown to suppress DC function through increase in IL-10 
and lower IL-12 production [61].   IL-12 is a potent pro-inflammatory cytokine that plays a 
key role in immune response against intracellular pathogens and Th1 cell differentiation 
whereas IL-10 is a signature anti-inflammatory cytokine that promotes Treg differentiation 
and is also produced by these cells playing a key role in maintaining immune homeostasis 
and resolution of inflammation post injury [62]. These data therefore strongly suggest that the 
‘hit’ monosaccharide primed DCs have acquired a tolerogenic phenotype which was further 
confirmed in DC-T cell co-cultured where conditioned DCs were shown to support naïve T 
cell differentiation towards Treg phenotype. It should be noted that the relatively high level 
of inter individual variation in cytokine levels between different donors meant that despite 
some marked changes in IL-12 or IL-10 levels in some donors these changes did not reach 
statistical significance. This could be due to presence of both high and low responders to 
monosaccharide combinations and/or LPS within the donor population [63]. To account for 
inter individual variation between different donors we normalised data for each donor to their 
data from LPS stimulation. 
The ability of ‘hit’ monosaccharide primed DCs in instructing downstream adaptive 
responses highlights the biological relevance of the monosaccharide conditioned DCs. Using 
engineered materials to modulate DC function has gained traction in the last few years with 
promising results in areas like DC based cancer vaccination [64, 65]. The ability to generate 
tolerogenic DCs and skew T cell responses towards Treg using immobilized monosaccharide 
combinations such as Gal1, Gal1-Gal2, Man1-Gal2, Man2-Gal2 and Man1-Man2 therefore 
provides exciting opportunities for using materials ‘decorated’ by as election of 
monosaccharides for promoting immune regulation in the context of inflammatory and 
autoimmune diseases as well as implanted materials. Conditions that showed reduction in 
CD40 and IDO activity together with increased IL10 or decreased both in IL12/IL10 were 
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selected as tolerogenic DCs and were taken forward for co-culture with DCs. 
T cells plasticity and their ability to respond to different signals and converging distinct 
signalling pathways is  a widely accepted concept, and provides opportunities for fine tuning 
their phenotype [66].  Interestingly, Gal1-Gal2 combination supported a significant increase 
in both IL-17 and IL-10 production. This is in line with previous work that has described 
regulatory T cells with the capacity to produce IL-17 to be highly immune suppressive and 
are believed to be related to tumour survival [67]. While future work should focus on better 
understanding the impact of monosaccharides on T cell polarisation and contribution of DCs 
in the observed increase in IL-10 production, the present data suggest that the Gal1-Gal2 
combination could prove a useful tool for developing new immunotherapies against 
inflammatory conditions where aberrant immune activation underpins tissue damage. 
Intriguingly, inclusion of mannose to either of Gal isoforms led to suppression of IL-17 
production while maintaining high IL-10 levels. This is broadly in line with the other studies 
showing mannose moieties support IL-10 production [61, 68].   
5. Conclusions 
In this study we screened a combinatorial library of immobilized monosaccharaides for their 
ability to modulate phenotypical and functional properties of DCs. This resulted in 
identifying a number of amino-monosaccharides (galactose and mannose with amines at 
positions 1 or 2; Gal1, Man1-Gal1, Man1-Gal2, Gal1-Gal2) that induce differentiation of 
tolerogenic DCs, able to support naïve T cell differentiation towards Treg phenotype. Our 
data also show the combination of 1-amino galactose and 2-amino galactose (Gal1-Gal2) 
primed DCs support Tregs that also produce high levels of IL-17, a T cell phenotype that is 
expected to be highly immune suppressive. The data will provide a basis of the rational 
design of monosaccharide coated surfaces with immune regulatory properties with the ability 
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to fine tune innate and adaptive immune responses with applications in materials-based 
immunotherapy for inflammatory conditions and implanted medical devices where 
suppressing immune responses is desirable. Future work should focus on investigating the 
efficacy of ‘hit’ monosaccharides in preclinical models.      
Acknowledgement 
We would like to acknowledge the support of the flowcytometry department (School of Life 
Sciences, University of Nottingham). This work was supported by a PhD studentship to 
MAA (Kuwait Civil Service Commission) and the EPSRC (Next Generation Biomaterials 
Discovery Program Grant; EP/N006615/1) to MRA and AMG.   
Data Availability 
All relevant data are available from the University of Nottingham’s Research Data 
Management Repository https://rdmc.nottingham.ac.uk    
 
Author Contributions 
MAA carried out experimental work, analyzed data and wrote the original draft of the 
manuscript. SJR carried out synthesis and fabrication of the immobilized monosaccharides 
libraries. AMG conceptualized the study. MRA, MIG and AMG supervised the study, wrote 
and revised the manuscript. All authors approved the final version of the manuscript.   
Conflict of Interests 
The authors have no conflict of interests to declare. 
 
 
References 
1. Franz S, Rammelt S, Scharnweber D, Simon JC: Immune responses to implants - a review of 
the implications for the design of immunomodulatory biomaterials. Biomaterials 2011, 
32(28):6692-6709. 
Jo
urn
al 
Pr
e-p
roo
f
29 
2. Sadtler K, Wolf MT, Ganguly S, Moad CA, Chung L, Majumdar S, Housseau F, Pardoll DM, 
Elisseeff JH: Divergent immune responses to synthetic and biological scaffolds. 
Biomaterials 2019, 192:405-415. 
3. Savina A, Amigorena S: Phagocytosis and antigen presentation in dendritic cells. Immunol 
Rev 2007, 219:143-156. 
4. Agrawal S, Gupta S, Agrawal A: Human Dendritic Cells Activated via Dectin-1 Are Efficient at 
Priming Th17, Cytotoxic CD8 T and B Cell Responses. PloS one 2010, 5(10):e13418. 
5. Schraml BU, Reis e Sousa C: Defining dendritic cells. Curr Opin Immunol 2015, 32:13-20. 
6. Macri C, Pang ES, Patton T, O'Keeffe M: Dendritic cell subsets. Semin Cell Dev Biol 2018, 
84:11-21. 
7. Dakappagari N, Maruyama T, Renshaw M, Tacken P, Figdor C, Torensma R, Wild MA, Wu D, 
Bowdish K, Kretz-Rommel A: Internalizing Antibodies to the C-Type Lectins, L-SIGN and DC-
SIGN, Inhibit Viral Glycoprotein Binding and Deliver Antigen to Human Dendritic Cells for 
the Induction of T Cell Responses. The Journal of Immunology 2006, 176(1):426-440. 
8. Varki A: Biological roles of glycans. Glycobiology 2017, 27(1):3-49. 
9. Hudak JE, Bertozzi CR: Glycotherapy: new advances inspire a reemergence of glycans in 
medicine. Chemistry & biology 2014, 21(1):16-37. 
10. Brown GD, Willment JA, Whitehead L: C-type lectins in immunity and homeostasis. Nat Rev 
Immunol 2018, 18(6):374-389. 
11. Martínez JD, Valverde P, Delgado S, Romanò C, Linclau B, Reichardt NC, Oscarson S, Ardá A, 
Jiménez-Barbero J, Cañada FJ: Unraveling Sugar Binding Modes to DC-SIGN by Employing 
Fluorinated Carbohydrates. Molecules (Basel, Switzerland) 2019, 24(12):2337. 
12. Salazar F, Sewell HF, Shakib F, Ghaemmaghami AM: The role of lectins in allergic 
sensitization and allergic disease. J Allergy Clin Immunol 2013, 132(1):27-36. 
13. Salazar F, Hall L, Negm OH, Awuah D, Tighe PJ, Shakib F, Ghaemmaghami AM: The mannose 
receptor negatively modulates the Toll-like receptor 4-aryl hydrocarbon receptor-
indoleamine 2,3-dioxygenase axis in dendritic cells affecting T helper cell polarization. J 
Allergy Clin Immunol 2016, 137(6):1841-1851 e1842. 
14. Su H, Peng B, Zhang Z, Liu Z, Zhang Z: The Mycobacterium tuberculosis glycoprotein 
Rv1016c protein inhibits dendritic cell maturation, and impairs Th1 /Th17 responses during 
mycobacteria infection. Molecular Immunology 2019, 109:58-70. 
15. Sha S, Shi X, Deng G, Chen L, Xin Y, Ma Y: Mycobacterium tuberculosis Rv1987 induces Th2 
immune responses and enhances Mycobacterium smegmatis survival in mice. 
Microbiological Research 2017, 197:74-80. 
16. Salazar F, Ghaemmaghami AM: Allergen recognition by innate immune cells: critical role of 
dendritic and epithelial cells. Front Immunol 2013, 4:356. 
17. Hassan A, Pritchard DI, Ghaemmaghami AM: Human dendritic cell sequestration onto the 
Necator americanus larval sheath during ex-sheathing: a possible mechanism for immune 
privilege. Parasitology 2018, 145(9):1183-1190. 
18. Perez-Zsolt D, Cantero-Pérez J, Erkizia I, Benet S, Pino M, Serra-Peinado C, Hernández-
Gallego A, Castellví J, Tapia G, Arnau-Saz V et al: Dendritic Cells From the Cervical Mucosa 
Capture and Transfer HIV-1 via Siglec-1. Frontiers in Immunology 2019, 10(825). 
19. Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R, Muller AJ: 
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape 
in cancer. Cancer Immunol Immunother 2014, 63(7):721-735. 
20. Harden JL, Egilmez NK: Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity. 
Immunol Invest 2012, 41(6-7):738-764. 
21. Ye Z, Yue L, Shi J, Shao M, Wu T: Role of IDO and TDO in Cancers and Related Diseases and 
the Therapeutic Implications. J Cancer 2019, 10(12):2771-2782. 
22. Royer P, Emara M, Yang C, Al-Ghouleh A, Tighe P, Jones N, Sewell H, Shakib F, Martinez-
Pomares L, Ghaemmaghami A: The mannose receptor mediates the uptake of diverse 
Jo
urn
al
Pr
e-p
roo
f
30 
native allergens by dendritic cells and determines allergen-induced T cell polarization 
through modulation of IDO activity. J Immunol 2010, 185(3):1522-1531. 
23. Van der Leek AP, Yanishevsky Y, Kozyrskyj AL: The Kynurenine Pathway As a Novel Link 
between Allergy and the Gut Microbiome. Frontiers in Immunology 2017, 8. 
24. Rostam HM, Singh S, Vrana NE, Alexander MR, Ghaemmaghami AM: Impact of surface 
chemistry and topography on the function of antigen presenting cells. Biomater Sci 2015, 
3(3):424-441. 
25. Awuah D, Alobaid M, Latif A, Salazar F, Emes RD, Ghaemmaghami AM: The Cross-Talk 
between miR-511-3p and C-Type Lectin Receptors on Dendritic Cells Affects Dendritic Cell 
Function. Journal of Immunology 2019, 203(1):148-157. 
26. Biggs CI, Walker M, Gibson MI: “Grafting to” of RAFTed Responsive Polymers to Glass 
Substrates by Thiol–Ene and Critical Comparison to Thiol–Gold Coupling. 
Biomacromolecules 2016, 17(8):2626-2633. 
27. Richards SJ, Otten L, Gibson MI: Glycosylated gold nanoparticle libraries for label-free 
multiplexed lectin biosensing. Journal of Materials Chemistry B, Materials for Biology and 
Medicine 2016, 4(18):3046-3053. 
28. Richards S-J, Gibson MI: Optimization of the Polymer Coating for Glycosylated Gold 
Nanoparticle Biosensors to Ensure Stability and Rapid Optical Readouts. ACS Macro Letters 
2014, 3(10):1004-1008. 
29. Otten L, Vlachou D, Richards S-J, Gibson MI: Glycan heterogeneity on gold nanoparticles 
increases lectin discrimination capacity in label-free multiplexed bioassays. Analyst 2016, 
141(14):4305-4312. 
30. Won S, Richards S-J, Walker M, Gibson MI: Externally controllable glycan presentation on 
nanoparticle surfaces to modulate lectin recognition. Nanoscale Horizons 2017, 2(2):106-
109. 
31. Georgiou PG, Baker AN, Richards S-J, Laezza A, Walker M, Gibson MI: “Tuning aggregative 
versus non-aggregative lectin binding with glycosylated nanoparticles by the nature of the 
polymer ligand”. Journal of Materials Chemistry B 2020, 8(1):136-145. 
32. Tomás RMF, Gibson MI: Optimization and Stability of Cell–Polymer Hybrids Obtained by 
“Clicking” Synthetic Polymers to Metabolically Labeled Cell Surface Glycans. 
Biomacromolecules 2019, 20(7):2726-2736. 
33. Biggs CI, Edmondson S, Gibson MI: Thiol-ene immobilisation of carbohydrates onto glass 
slides as a simple alternative to gold-thiol monolayers, amines or lipid binding. 
Biomaterials Science 2015, 3(1):175-181. 
34. Aldajani WA, Salazar F, Sewell HF, Knox A, Ghaemmaghami AM: Expression and regulation 
of immune-modulatory enzyme indoleamine 2,3-dioxygenase (IDO) by human airway 
epithelial cells and its effect on T cell activation. Oncotarget 2016, 7(36):57606-57617. 
35. Salazar F, Awuah D, Negm OH, Shakib F, Ghaemmaghami AM: The role of indoleamine 2,3-
dioxygenase-aryl hydrocarbon receptor pathway in the TLR4-induced tolerogenic 
phenotype in human DCs. Sci Rep 2017, 7:43337. 
36. Sharma V, Ichikawa M, Freeze HH: Mannose metabolism: more than meets the eye. 
Biochemical and biophysical research communications 2014, 453(2):220-228. 
37. van Mierlo GJD, den Boer AT, Medema JP, van der Voort EIH, Fransen MF, Offringa R, Melief 
CJM, Toes REM: CD40 stimulation leads to effective therapy of CD40(-) tumors through 
induction of strong systemic cytotoxic T lymphocyte immunity. Proceedings of the National 
Academy of Sciences of the United States of America 2002, 99(8):5561-5566. 
38. Morgado P, Sudarshana DM, Gov L, Harker KS, Lam T, Casali P, Boyle JP, Lodoen MB: Type II 
Toxoplasma gondii induction of CD40 on infected macrophages enhances interleukin-12 
responses. Infect Immun 2014, 82(10):4047-4055. 
39. Chellappa S, Hugenschmidt H, Hagness M, Line PD, Labori KJ, Wiedswang G, Taskén K, 
Aandahl EM: Regulatory T cells that co-express RORγt and FOXP3 are pro-inflammatory 
Jo
urn
al 
Pr
-pr
oo
f
31 
and immunosuppressive and expand in human pancreatic cancer. Oncoimmunology 2015, 
5(4):e1102828-e1102828. 
40. Vishwakarma A, Bhise NS, Evangelista MB, Rouwkema J, Dokmeci MR, Ghaemmaghami AM, 
Vrana NE, Khademhosseini A: Engineering Immunomodulatory Biomaterials To Tune the 
Inflammatory Response. Trends Biotechnol 2016, 34(6):470-482. 
41. Vegas AJ, Veiseh O, Doloff JC, Ma M, Tam HH, Bratlie K, Li J, Bader AR, Langan E, Olejnik K et 
al: Combinatorial hydrogel library enables identification of materials that mitigate the 
foreign body response in primates. Nat Biotechnol 2016, 34(3):345-352. 
42. Veiseh O, Doloff JC, Ma M, Vegas AJ, Tam HH, Bader AR, Li J, Langan E, Wyckoff J, Loo WS et 
al: Size- and shape-dependent foreign body immune response to materials implanted in 
rodents and non-human primates. Nat Mater 2015, 14(6):643-651. 
43. Vassey MJ, Figueredo GP, Scurr DJ, Vasilevich AS, Vermeulen S, Carlier A, Luckett J, Beijer 
NRM, Williams P, Winkler DA et al: Immune Modulation by Design: Using Topography to 
Control Human Monocyte Attachment and Macrophage Differentiation. Adv Sci (Weinh) 
2020, 7(11):1903392. 
44. Hassan M Rostam LEF, Andrew L Hook, Laurence Burroughs, Jeni C Luckett, Grazziela P 
Figueredo, Chidimma Mbadugha, Alvin CK Teo, Arsalan LAtif, Lisa Kammerling, Mitchell Day, 
Karen Lawler, David Barrett, Somaia Elsheikh, Mohammad Ilyas, DAvid A Winkler, Morgan R 
Alexander, Amir M Ghaemmaghami: Immune-Instructive Polymers Control Macrophage 
Phenotype and Modulate the Foreign Body Response In Vivo. Matter 2020, 2(6):1564-
1581. 
45. Sadtler K, Estrellas K, Allen BW, Wolf MT, Fan H, Tam AJ, Patel CH, Luber BS, Wang H, 
Wagner KR et al: Developing a pro-regenerative biomaterial scaffold microenvironment 
requires T helper 2 cells. Science 2016, 352(6283):366-370. 
46. Keselowsky BG, Lewis JS: Dendritic cells in the host response to implanted materials. Semin 
Immunol 2017, 29:33-40. 
47. El Ghazal R, Yin X, Johns SC, Swanson L, Macal M, Ghosh P, Zuniga EI, Fuster MM: Glycan 
Sulfation Modulates Dendritic Cell Biology and Tumor Growth. Neoplasia 2016, 18(5):294-
306. 
48. Kreisman LS, Cobb BA: Infection, inflammation and host carbohydrates: a Glyco-Evasion 
Hypothesis. Glycobiology 2012, 22(8):1019-1030. 
49. Eastman AJ, Osterholzer JJ, Olszewski MA: Role of dendritic cell-pathogen interactions in 
the immune response to pulmonary cryptococcal infection. Future Microbiol 2015, 
10(11):1837-1857. 
50. Ghaemmaghami AM, Gough L, Sewell HF, Shakib F: The proteolytic activity of the major 
dust mite allergen Der p 1 conditions dendritic cells to produce less interleukin-12: 
allergen-induced Th2 bias determined at the dendritic cell level. Clin Exp Allergy 2002, 
32(10):1468-1475. 
51. Shen X, Zhang L, Li J, Li Y, Wang Y, Xu ZX: Recent Findings in the Regulation of Programmed 
Death Ligand 1 Expression. Front Immunol 2019, 10:1337. 
52. Hamilton CM, Dowling DJ, Loscher CE, Morphew RM, Brophy PM, O'Neill SM: The 
<em>Fasciola hepatica</em> Tegumental Antigen Suppresses Dendritic Cell Maturation 
and Function. Infection and Immunity 2009, 77(6):2488-2498. 
53. Brenk M, Scheler M, Koch S, Neumann J, Takikawa O, Hacker G, Bieber T, von Bubnoff D: 
Tryptophan deprivation induces inhibitory receptors ILT3 and ILT4 on dendritic cells 
favoring the induction of human CD4+CD25+ Foxp3+ T regulatory cells. Journal of 
immunology (Baltimore, Md : 1950) 2009, 183(1):145-154. 
54. Hoshi M, Saito K, Hara A, Taguchi A, Ohtaki H, Tanaka R, Fujigaki H, Osawa Y, Takemura M, 
Matsunami H et al: The Absence of IDO Upregulates Type I IFN Production, Resulting in 
Suppression of Viral Replication in the Retrovirus-Infected Mouse. The Journal of 
Immunology 2010, 185(6):3305-3312. 
J
urn
al 
Pr
-pr
of
32 
55. Terness P, Bauer TM, Rose L, Dufter C, Watzlik A, Simon H, Opelz G: Inhibition of allogeneic 
T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation 
of suppression by tryptophan metabolites. The Journal of Experimental Medicine 2002, 
196(4):447-457. 
56. Hwang SL, Chung NP-Y, Chan JK-Y, Lin C-LS: Indoleamine 2, 3-dioxygenase (IDO) is essential 
for dendritic cell activation and chemotactic responsiveness to chemokines. Cell Research 
2005, 15(3):167-175. 
57. Labadie BW, Bao R, Luke JJ: Reimagining IDO Pathway Inhibition in Cancer Immunotherapy 
via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis. Clinical 
Cancer Research 2019, 25(5):1462. 
58. Maleki Vareki S, Chen D, Di Cresce C, Ferguson PJ, Figueredo R, Pampillo M, Rytelewski M, 
Vincent M, Min W, Zheng X et al: IDO Downregulation Induces Sensitivity to Pemetrexed, 
Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells. PloS one 2015, 
10(11):e0143435. 
59. Immunotherapies for autoimmune diseases. Nat Biomed Eng 2019, 3(4):247. 
60. Ravishankar B, Liu H, Shinde R, Chandler P, Baban B, Tanaka M, Munn DH, Mellor AL, 
Karlsson MC, McGaha TL: Tolerance to apoptotic cells is regulated by indoleamine 2,3-
dioxygenase. Proc Natl Acad Sci U S A 2012, 109(10):3909-3914. 
61. Geijtenbeek  TBH, van Vliet  SJ, Koppel  EA, Sanchez-Hernandez  M, Vandenbroucke-Grauls  
CMJE, Appelmelk  B, van Kooyk  Y: Mycobacteria Target DC-SIGN to Suppress Dendritic Cell 
Function. Journal of Experimental Medicine 2002, 197(1):7-17. 
62. Ma X, Yan W, Zheng H, Du Q, Zhang L, Ban Y, Li N, Wei F: Regulation of IL-10 and IL-12 
production and function in macrophages and dendritic cells. F1000Res 2015, 4. 
63. Wurfel MM, Park WY, Radella F, Ruzinski J, Sandstrom A, Strout J, Bumgarner RE, Martin TR: 
Identification of High and Low Responders to Lipopolysaccharide in Normal Subjects: An 
Unbiased Approach to Identify Modulators of Innate Immunity. The Journal of Immunology 
2005, 175(4):2570-2578. 
64. Kim J, Mooney DJ: In Vivo Modulation of Dendritic Cells by Engineered Materials: Towards 
New Cancer Vaccines. Nano Today 2011, 6(5):466-477. 
65. Shah NJ, Najibi AJ, Shih TY, Mao AS, Sharda A, Scadden DT, Mooney DJ: A biomaterial-based 
vaccine eliciting durable tumour-specific responses against acute myeloid leukaemia. Nat 
Biomed Eng 2020, 4(1):40-51. 
66. Murphy KM, Stockinger B: Effector T cell plasticity: flexibility in the face of changing 
circumstances. Nature immunology 2010, 11(8):674-680. 
67. Downs-Canner S, Berkey S, Delgoffe GM, Edwards RP, Curiel T, Odunsi K, Bartlett DL, 
Obermajer N: Suppressive IL-17A+Foxp3+ and ex-Th17 IL-17AnegFoxp3+ Treg cells are a 
source of tumour-associated Treg cells. Nature Communications 2017, 8(1):14649. 
68. Rodríguez E, Kalay H, Noya V, Brossard N, Giacomini C, van Kooyk Y, García-Vallejo JJ, Freire 
T: Fasciola hepatica glycoconjugates immuneregulate dendritic cells through the Dendritic 
Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin inducing T cell 
anergy. Scientific Reports 2017, 7(1):46748. 
 
 
Jo
urn
l P
r -
pro
of
Declaration of interests 
 
☒ The authors declare that they have no known competing financial interests or personal relationships 
that could have appeared to influence the work reported in this paper. 
 
☐The authors declare the following financial interests/personal relationships which may be considered 
as potential competing interests:  
 
 
 
 
 
 
Jo
urn
al 
Pr
e-p
roo
f
